AR069538A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES - Google Patents

PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES

Info

Publication number
AR069538A1
AR069538A1 ARP080103048A ARP080103048A AR069538A1 AR 069538 A1 AR069538 A1 AR 069538A1 AR P080103048 A ARP080103048 A AR P080103048A AR P080103048 A ARP080103048 A AR P080103048A AR 069538 A1 AR069538 A1 AR 069538A1
Authority
AR
Argentina
Prior art keywords
agent
benzisoxazolic
indicated
treatment
pharmaceutical composition
Prior art date
Application number
ARP080103048A
Other languages
Spanish (es)
Inventor
Armenta Maria Elena Garcia
Murillo Josefina Santos
Ochoa Victor Guillermo Alvarez
Original Assignee
World Trade Imp Export Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by World Trade Imp Export Wtie Ag filed Critical World Trade Imp Export Wtie Ag
Publication of AR069538A1 publication Critical patent/AR069538A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion farmacéutica compuesta por la combinacion sinérgica de un agente derivado benzisoxazolico, como lo es el principio activo: Risperidona y un agente inhibidor reversible de colinesterasa, como lo es el principio activo: Donepezilo; los cuales se encuentran formulados en una sola unidad de dosificacion para ser administrada por vía oral en forma de cápsula o tableta; misma que está indicada para el control y tratamiento de enfermedades tales como: trastornos psicoticos, como la esquizofrenia. demencia vascular, demencia del tipo de Alzheimer y otras enfermedades relacionadas.Pharmaceutical composition composed of the synergistic combination of a benzisoxazolic derivative agent, such as the active substance: Risperidone and a reversible cholinesterase inhibitor, such as the active substance: Donepezil; which are formulated in a single dosage unit to be administered orally in capsule or tablet form; It is indicated for the control and treatment of diseases such as: psychotic disorders, such as schizophrenia. Vascular dementia, Alzheimer's type dementia and other related diseases.

ARP080103048A 2007-07-16 2008-07-16 PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES AR069538A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2007008642A MX2007008642A (en) 2007-07-16 2007-07-16 Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias.
PCT/MX2008/000092 WO2009011560A1 (en) 2007-07-16 2008-07-16 Pharmaceutical composition combining risperidone and donepezil, and use thereof for treating psychotic disorders such as schizophrenia and dimentias such as alzheimer's disease

Publications (1)

Publication Number Publication Date
AR069538A1 true AR069538A1 (en) 2010-02-03

Family

ID=40259824

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103048A AR069538A1 (en) 2007-07-16 2008-07-16 PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES

Country Status (4)

Country Link
AR (1) AR069538A1 (en)
MX (1) MX2007008642A (en)
UY (1) UY31231A1 (en)
WO (1) WO2009011560A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010072878A (en) * 1998-10-16 2001-07-31 디르크 반테 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations

Also Published As

Publication number Publication date
MX2007008642A (en) 2009-02-25
UY31231A1 (en) 2009-01-05
WO2009011560A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
SV2010003491A (en) 2- ANILINOPURIN-8-ONAS AS INHIBITORS OF TTK / MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
ES2916649T1 (en) Compositions and uses for the treatment of multiple sclerosis
AR093247A1 (en) PROFILACTIC AND / OR THERAPEUTIC AGENT FOR BEHAVIOR AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL ILLNESS CONTAINING BREXPIPRAZOL OR SALTS OF THE SAME
AR070047A1 (en) THERAPEUTIC TREATMENTS AGAINST CANCER. COMPOSITION THAT INCLUDES A HEDGEHOG INHIBITOR.
CL2013001136A1 (en) A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent.
AR085662A1 (en) METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA
AR060019A1 (en) PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
AR076300A1 (en) DERIVATIVES OF PIRIMIDIN REPLACED IMIDAZOLS, INHIBITORS OF GSK3, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME IN THE TREATMENT OF ALZHEIMER, ACUTE NEURODEGENERATIVE DISEASES, DIABETES AND OTHER DISEASES.
AR068745A1 (en) A COMPOSITION IN THE FORM OF ORAL PHARMACEUTICAL DOSAGE OF HIGH DOSAGE UNIT OF SODIUM MYCOPHENOLATE, METHOD FOR USING SUCH COMPOSITION AND ITS USES
BR112016026667A8 (en) orally disintegrating tablet for administration of avanafil, associated methods of manufacturing and use of a pdev inhibitor.
DOP2006000287A (en) PIPERIDINE DERIVATIVES
PE20151543A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF SULPHATE SALTS FOR DUAL USE TABLETS AND METHODS FOR ITS USE
AR083095A1 (en) APREPITANT L-PROLINA AND PHARMACEUTICAL COMPOSITION CO-CRYSTAL
AR107935A1 (en) USE OF COMPOUND 6- (4- (2,3-DIMETHYLPHENOXY) PIPERIDIN-1-IL) METHYL) PYRIMIDINE-2,4 (1H, 3H) -DIONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME TO PREPARE A MEDICINAL, COMBINATION AND COMPOSITION PHARMACEUTICAL UNDERSTANDING SUCH COMPOUND
AR088845A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 7- (1H-IMIDAZOL-4-ILMETIL) -5,6,7,8-TETRAHYDRO-QUINOLINE FOR THE TREATMENT OF SKIN DISEASES AND AFFECTIONS
AR074246A1 (en) DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF SOIL DISORDERS
UY31363A1 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF AN NON-STEROID ANTIFLAMMATORY AGENT AND AN INHIBITING AGENT OF THE XANTINO OXIDASE USEFUL FOR THE CONTROL AND TREATMENT OF THE DROP, GOTOUS ARTHRITIS AND RELATED DISEASES
DOP2010000265A (en) ORAL GALENIC FORMULATION INCLUDING KETOROLACO AND VITAMINS OF COMPLEX B, IN WHICH VITAMIN B6 IS FOUND AN EXTERNAL LAYER SEPARATED FROM THE REST OF ACTIVE PRINCIPLES
AR069538A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A REVERSIBLE INHIBITING AGENT OF CHOLINESTERASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF PSYCHOTIC DISORDERS AND DEMENCIES
AR067465A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF A BENZISOXAZOLIC DERIVATIVE AGENT AND A BENZODIAZEPINIC AGENT
GT200900275A (en) SYNERGIC PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF AN INHIBITOR OF ENZYME 5 A-REDUCTASE AND AN ANTAGONIST OF RECEIVERS 1 A-ANDRENÉRGICOS.
UY31153A1 (en) COMBINED PHARMACEUTICAL COMPOSITION
PE20090725A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTI-ARTHRITIC AGENT AND AN INTERLEUKIN-1 INHIBITING AGENT, USEFUL FOR THE CONTROL AND TREATMENT OF OSTEOARTHROSIS AND RELATED DISEASES
ECSP109996A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTIMICROBIAL AGENT AND A SELECTIVE INHIBITING AGENT OF THE ENCEPHALINASE ENZYME, INDICATED FOR THE CONTROL AND TREATMENT OF THE ACUTE BACTERIAL DIARRHEA
UY31248A1 (en) PHARMACEUTICAL COMPOSITION UNDERSTANDING THE COMBINATION OF AN ANTIANDROGEN AGENT, A SYNTHETIC STERETIC STROGEN AGENT AND VITAMINAL AGENTS, USEFUL FOR THE CONTROL AND TREATMENT OF LATE ACNE IN WOMEN

Legal Events

Date Code Title Description
FB Suspension of granting procedure